TaiMed Biologics (ROCO:4147) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4147 TaiMed Biologics Inc ROCO:4147
67 GF Score
Price NT$59.10
GF Value NT$80.54
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics 5-Year Yield-on-Cost %?

TaiMed Biologics ROCO:4147 +2.60% 67 5-Year Yield-on-Cost % is 0.00 as of Aug. 06, 2026. GuruFocus rates ROCO:4147 with a GF Score™ of 67/100 and a GF Value™ of NT$80.54 (Modestly Undervalued). Among 150 Biotechnology companies, TaiMed Biologics ranks worse than 666666% on this metric.

TaiMed Biologics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for TaiMed Biologics's 5-Year Yield-on-Cost % or its related term are showing as below:



ROCO:4147's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.685
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

TaiMed Biologics  (ROCO:4147) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


TaiMed Biologics 5-Year Yield-on-Cost % Related Terms


ROCO:4147 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, TaiMed Biologics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiMed Biologics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's 5-Year Yield-on-Cost % falls into.


ROCO:4147
67GF Score
TaiMed Biologics Inc ROCO:4147
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of TaiMed Biologics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
TaiMed Biologics (ROCO:4147) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TaiMed Biologics and its competitors. According to the industry distribution chart, TaiMed Biologics ranks #999999 out of 150 companies in the Biotechnology industry.
Is TaiMed Biologics' 5-Year Yield-on-Cost % too high?
TaiMed Biologics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, TaiMed Biologics ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TaiMed Biologics has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places TaiMed Biologics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.69, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TaiMed Biologics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$80.54, compared to a current price of NT$59.10 — trading 26.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. TaiMed Biologics' overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$59.10 is trading 26.6% below its estimated GF Value™ of NT$80.54. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: NT$80.54 vs. price of NT$59.10 (26.6% below fair value)
  • GF Score™: 67/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
67GF Score

Get the complete analysis for ROCO:4147

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$59.10
Price
NT$80.54
GF Value